Annual Meeting Proceedings II - Newly Released Abstracts for
Annual Meeting Proceedings II - Newly Released Abstracts for
Annual Meeting Proceedings II - Newly Released Abstracts for
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
2 Plenary Session, Sun, 1:00 PM-4:00 PM<br />
Long-term follow-up results of EORTC 26951: A randomized phase <strong>II</strong>I study on<br />
adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).<br />
Martin J. Van Den Bent, Khê Hoang-Xuan, Alba Ariela Brandes, Johan M Kros,<br />
Mathilde C.M. Kouwenhoven, Martin J. B. Taphoorn, Jean-Yves Delattre, Hans J.J.B. Bernsen,<br />
Marc Frenay, Cees Tijssen, Wolfgang Grisold, Laszlo Sipos, Roelien H. Enting, Winand N.M. Dinjens,<br />
Pim French, Charles J Vecht, Anouk Allgeier, Denis A. Lacombe, Thierry Gorlia; Erasmus University<br />
Medical Center, Daniel den Hoed Cancer Center, Rotterdam, Netherlands; Groupe Hospitalier Pitié-<br />
Salpêtrière, Paris, France; Medical Oncology Department, Bellaria-Maggiore Hospital, Azienda USL of<br />
Bologna, Bologna, Italy; Erasmus Medical Center, Rotterdam, Netherlands; Erasmus University Medical<br />
Center, Rotterdam, Netherlands; Medical Center Haaglanden/VU Medical Center, The Hague/Amsterdam,<br />
Netherlands; Pitie-Salpetriere Hospital-Pierre et Marie Curie Paris VI University, Paris, France; Canisius<br />
Wilhelmina Ziekenhuis, Nijmegen, Netherlands; Anticancer Center, Centre Antoine-Lacassagne, Nice,<br />
France; Elisabeth Gasthuis, Tilburg, Netherlands; Kaiser Franz Josef Hospital, Vienna, Austria; Neurooncologist<br />
National Institute of Neurosciences, Budapest, Hungary; Universitair Medisch Centrum Groningen,<br />
Groningen, Netherlands; Erasmus MC, Rotterdam, Netherlands; Medical Center The Hague, The<br />
Hague, Netherlands; European Organisation <strong>for</strong> Research and Treatment of Cancer Headquarters,<br />
Brussels, Belgium<br />
Background: AOD are chemotherapy-sensitive tumors especially if 1p/19q co-deleted. Between 1995 and<br />
2002 the EORTC Brain Tumor Group conducted a prospective phase <strong>II</strong>I study on adjuvant procarbazine,<br />
CCNU and vincristine chemotherapy (PCV) in AOD. We now present long-term follow-up. Methods:<br />
Patients (pts) with locally diagnosed newly diagnosed AOD were randomized between radiotherapy (RT, 33<br />
x 1.8 Gy) and the same RT followed by 6 cycles of standard PCV (RT/PCV). Primary endpoints were<br />
overall survival (OS) and progression-free survival (PFS). 1p/19q status, IDH status and MGMT promoter<br />
methylation were determined in 300, 167, and 186 pts respectively. Results: Between 1996 and 2002, 368<br />
pts were included. At the time of analysis 281 pts (76.4%) had died. Median PFS after RT/PCV was<br />
significantly longer compared to RT alone (24.3 months versus 13.21 months, hazard ratio [HR] 0.66, [95%<br />
confidence interval (95% CI) 0.52, 0.83]). More RT arm patients received chemotherapy at progression<br />
(75% vs 53%). Median OS was also significantly prolonged in the RT/PCV arm (42.3 months vs 30.6<br />
months <strong>for</strong> the RT arm, HR 0.75 [95% CI 0.60, 0.95]). 1p/19q co-deleted patients (n � 76) treated with<br />
RT/PCV had improved OS compared to RT arm pts (median OS not reached vs 113 months; HR 0.54, p<br />
� 0.0487). In the 224 patients without 1p/19q co-deletion the difference in OS was non-significant (OS<br />
RT/PCV arm 25 months vs 22 months in the RT arm, HR 0.82, p � 0.18; test <strong>for</strong> interaction p � 0.22).<br />
There was a slight trend towards improved OS in MGMT methylated and IDH mutated tumors versus<br />
unmethylated and IDH wild type tumors (Table). Conclusions: The addition of PCV to RT increases PFS<br />
and OS in AOD. Pts with 1p/19q co-deletion appear to benefit most from the addition of PCV, with a trend<br />
<strong>for</strong> improved OS in pts with MGMT methylation and IDH mutations.<br />
Molecular features and the HR reduction <strong>for</strong> OS in the RT/PCV arm.<br />
Feature Status N HR 95% CI Status N HR 95% CI P<br />
1p/19q Co-deleted 76 0.54 0.29, 1.01 Intact 224 0.82 0.61, 1.10 0.22<br />
MGMT Methylated 132 0.67 0.44, 1.01 Unmethylated 54 0.80 0.46, 1.42 0.6<br />
IDH Mutated 77 0.59 0.33, 1.07 Wild type 90 0.72 0.46, 1.11 0.58<br />
Abbreviations: n: number of pts; p: p value interaction test.<br />
CENTRAL NERVOUS SYSTEM TUMORS<br />
© 2012 American Society of Clinical Oncology. Reprinted with permission.